207 related articles for article (PubMed ID: 26881752)
1. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.
Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR
Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752
[TBL] [Abstract][Full Text] [Related]
2. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
Toussaint ND; Damasiewicz MJ
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Herencia C; López-Baltanás R; Jurado-Montoya D; García-Saez RM; Valdés-Díaz K; Martínez-Moreno JM; Santamaría R; Pendón-Ruiz de Mier MV; Rodelo-Haad C; Frazão JM; Felsenfeld AJ; Rodríguez M; Almadén Y; Muñoz-Castañeda JR
FASEB J; 2024 Jun; 38(11):e23726. PubMed ID: 38847773
[TBL] [Abstract][Full Text] [Related]
5. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
Newman CL; Creecy A; Granke M; Nyman JS; Tian N; Hammond MA; Wallace JM; Brown DM; Chen N; Moe SM; Allen MR
Kidney Int; 2016 Jan; 89(1):95-104. PubMed ID: 26489025
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
11. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
13. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.
Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR
Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482
[TBL] [Abstract][Full Text] [Related]
14. Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease.
Evenepoel P; Jørgensen HS
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):383-390. PubMed ID: 38651491
[TBL] [Abstract][Full Text] [Related]
15. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
16. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
[TBL] [Abstract][Full Text] [Related]
18. Magnesium Modifies the Impact of Calcitriol Treatment on Vascular Calcification in Experimental Chronic Kidney Disease.
Zelt JG; McCabe KM; Svajger B; Barron H; Laverty K; Holden RM; Adams MA
J Pharmacol Exp Ther; 2015 Dec; 355(3):451-62. PubMed ID: 26487689
[TBL] [Abstract][Full Text] [Related]
19. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
20. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
Sanchez CP; He YZ
J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
